• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

内皮素 A 受体在肾单位中的破坏导致轻度液体容量扩张。

Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion.

机构信息

Division of Nephrology, University of Utah Health Sciences Center, 1900 East 30 North, Salt Lake City, UT 84132, USA.

出版信息

BMC Nephrol. 2012 Dec 5;13:166. doi: 10.1186/1471-2369-13-166.

DOI:10.1186/1471-2369-13-166
PMID:23217151
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3537641/
Abstract

BACKGROUND

Endothelin, via endothelin A receptors (ETA), exerts multiple pathologic effects that contribute to disease pathogenesis throughout the body. ETA antagonists ameliorate many experimental diseases and have been extensively utilized in clinical trials. The utility of ETA blockers has been greatly limited, however, by fluid retention, sometimes leading to heart failure or death. To begin to examine this issue, the effect of genetic disruption of ETA in the nephron on blood pressure and salt handling was determined.

METHODS

Mice were generated with doxycycline-inducible nephron-specific ETA deletion using Pax8-rtTA and LC-1 transgenes on the background of homozygous loxP-flanked ETA alleles. Arterial pressure, Na metabolism and measures of body fluid volume status (hematocrit and impedance plethysmography) were assessed.

RESULTS

Absence of nephron ETA did not alter arterial pressure whether mice were ingesting a normal or high Na diet. Nephron ETA disruption did not detectably affect 24 hr Na excretion or urine volume regardless of Na intake. However, mice with nephron ETA knockout that were fed a high Na diet had mild fluid retention as evidenced by an increase in body weight and a fall in hematocrit.

CONCLUSIONS

Genetic deletion of nephron ETA causes very modest fluid retention that does not alter arterial pressure. Nephron ETA, under normal conditions, likely do not play a major role in regulation of Na excretion or systemic hemodynamics.

摘要

背景

内皮素通过内皮素 A 受体(ETA)发挥多种病理作用,这些作用有助于全身疾病的发病机制。ETA 拮抗剂改善了许多实验性疾病,并已广泛应用于临床试验。然而,ETA 阻滞剂的应用受到限制,因为它会导致液体潴留,有时会导致心力衰竭或死亡。为了开始研究这个问题,研究人员确定了内皮素在肾单位中的遗传缺失对血压和盐处理的影响。

方法

使用 Pax8-rtTA 和 LC-1 转基因,在同源性loxP 侧翼 ETA 等位基因的背景下,生成可诱导内皮素 A 受体(ETA)在肾单位中特异性缺失的小鼠。评估了动脉压、Na 代谢和体液容量状态的测量(血细胞比容和阻抗体积描记法)。

结果

无论小鼠摄入正常或高 Na 饮食,肾单位 ETA 的缺失都不会改变动脉压。无论 Na 摄入量如何,肾单位 ETA 缺失都不会明显影响 24 小时 Na 排泄或尿量。然而,在高盐饮食下,肾单位 ETA 敲除的小鼠有轻度的液体潴留,表现为体重增加和血细胞比容下降。

结论

肾单位内皮素 A 受体的基因缺失导致非常轻微的液体潴留,不会改变动脉压。在正常情况下,肾单位内皮素 A 受体可能不会在 Na 排泄或全身血液动力学的调节中发挥主要作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0738/3537641/06003450e963/1471-2369-13-166-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0738/3537641/05ceacddd4c6/1471-2369-13-166-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0738/3537641/ea80e96c1ae7/1471-2369-13-166-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0738/3537641/19f103039140/1471-2369-13-166-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0738/3537641/c29c4b04f61a/1471-2369-13-166-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0738/3537641/06003450e963/1471-2369-13-166-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0738/3537641/05ceacddd4c6/1471-2369-13-166-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0738/3537641/ea80e96c1ae7/1471-2369-13-166-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0738/3537641/19f103039140/1471-2369-13-166-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0738/3537641/c29c4b04f61a/1471-2369-13-166-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0738/3537641/06003450e963/1471-2369-13-166-6.jpg

相似文献

1
Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion.内皮素 A 受体在肾单位中的破坏导致轻度液体容量扩张。
BMC Nephrol. 2012 Dec 5;13:166. doi: 10.1186/1471-2369-13-166.
2
Myocardial, smooth muscle, nephron, and collecting duct gene targeting reveals the organ sites of endothelin A receptor antagonist fluid retention.心肌、平滑肌、肾单位和集合管基因靶向揭示内皮素 A 受体拮抗剂水潴留的器官部位。
J Pharmacol Exp Ther. 2013 Aug;346(2):182-9. doi: 10.1124/jpet.113.205286. Epub 2013 May 24.
3
Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention.集合管内皮素A和B受体联合敲除导致高血压和钠潴留。
Am J Physiol Renal Physiol. 2008 Dec;295(6):F1635-40. doi: 10.1152/ajprenal.90279.2008. Epub 2008 Sep 10.
4
Possible role for nephron-derived angiotensinogen in angiotensin-II dependent hypertension.肾单位源性血管紧张素原在血管紧张素 II 依赖性高血压中的可能作用。
Physiol Rep. 2016 Jan;4(1). doi: 10.14814/phy2.12675.
5
Nephron-Specific Disruption of Polycystin-1 Induces Cyclooxygenase-2-Mediated Blood Pressure Reduction Independent of Cystogenesis.多囊蛋白-1 肾单位特异性敲除诱导环氧化酶-2 介导的血压降低,与囊肿形成无关。
J Am Soc Nephrol. 2020 Jun;31(6):1243-1254. doi: 10.1681/ASN.2019090934. Epub 2020 Apr 16.
6
Lack of an effect of nephron-specific deletion of adenylyl cyclase 3 on renal sodium and water excretion or arterial pressure.肾特异性敲除腺苷酸环化酶3对肾钠和水排泄或动脉血压无影响。
Physiol Rep. 2015 Mar;3(3). doi: 10.14814/phy2.12316.
7
Smooth muscle specific disruption of the endothelin-A receptor in mice reduces arterial pressure, and vascular reactivity and affects vascular development.小鼠体内内皮素 A 受体的平滑肌特异性破坏会降低动脉血压、血管反应性并影响血管发育。
Life Sci. 2014 Nov 24;118(2):238-43. doi: 10.1016/j.lfs.2013.12.209. Epub 2014 Jan 8.
8
Endothelin ET Receptor Blockade, by Activating ET Receptors, Increases Vascular Permeability and Induces Exaggerated Fluid Retention.内皮素(ET)受体阻断通过激活ET受体,增加血管通透性并导致过度的液体潴留。
J Pharmacol Exp Ther. 2017 May;361(2):322-333. doi: 10.1124/jpet.116.234930. Epub 2017 Feb 21.
9
Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure.内皮素A受体在集合管特异性敲除可改变肾脏对血管加压素的反应性,但不影响钠排泄或血压。
Am J Physiol Renal Physiol. 2005 Oct;289(4):F692-8. doi: 10.1152/ajprenal.00100.2005. Epub 2005 May 31.
10
Nephron-specific deletion of the prorenin receptor causes a urine concentration defect.肾素原受体在肾单位特异性缺失会导致尿液浓缩功能缺陷。
Am J Physiol Renal Physiol. 2015 Jul 1;309(1):F48-56. doi: 10.1152/ajprenal.00126.2015. Epub 2015 May 20.

引用本文的文献

1
Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application.慢性肾脏病中的选择性内皮素A受体拮抗作用:改善临床应用
Nephrol Dial Transplant. 2025 Feb 5;40(Supplement_1):i37-i46. doi: 10.1093/ndt/gfae214.
2
Endothelin receptor antagonists in chronic kidney disease.慢性肾脏病中的内皮素受体拮抗剂
Nat Rev Nephrol. 2025 Mar;21(3):175-188. doi: 10.1038/s41581-024-00908-z. Epub 2024 Dec 6.
3
The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy: A Randomized Double-Blind Placebo-Controlled Clinical Trial.

本文引用的文献

1
Collecting duct-specific endothelin B receptor knockout increases ENaC activity.集合管特异性内皮素 B 受体敲除增加 ENaC 活性。
Am J Physiol Cell Physiol. 2012 Jan 1;302(1):C188-94. doi: 10.1152/ajpcell.00301.2011. Epub 2011 Sep 14.
2
Endothelin antagonists in clinical trials: lessons learned.临床试验中的内皮素拮抗剂:经验教训
Contrib Nephrol. 2011;172:255-260. doi: 10.1159/000328859. Epub 2011 Aug 30.
3
Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.阿曲生坦联合肾素-血管紧张素系统阻断剂可减少糖尿病肾病患者的蛋白尿。
选择性内皮素受体拮抗剂SC0062治疗IgA肾病:一项随机双盲安慰剂对照临床试验
J Am Soc Nephrol. 2025 Apr 1;36(4):657-667. doi: 10.1681/ASN.0000000538. Epub 2024 Oct 26.
4
Comprehensive analysis of the endothelin system in the kidneys of mice, rats, and humans.全面分析小鼠、大鼠和人类肾脏中的内皮素系统。
Biosci Rep. 2024 Jul 31;44(7). doi: 10.1042/BSR20240768.
5
Renomedullary Interstitial Cell Endothelin A Receptors Regulate BP and Renal Function.肾髓质间质细胞内皮素 A 受体调节血压和肾功能。
J Am Soc Nephrol. 2020 Jul;31(7):1555-1568. doi: 10.1681/ASN.2020020232. Epub 2020 Jun 2.
6
The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.糖尿病肾病的新生物学:机制与治疗意义。
Endocr Rev. 2020 Apr 1;41(2):202-31. doi: 10.1210/endrev/bnz010.
7
Activation of purinergic receptors (P2) in the renal medulla promotes endothelin-dependent natriuresis in male rats.肾髓质中嘌呤能受体(P2)的激活促进雄性大鼠内皮素依赖性利钠作用。
Am J Physiol Renal Physiol. 2016 Aug 1;311(2):F260-7. doi: 10.1152/ajprenal.00090.2016. Epub 2016 May 25.
8
Endothelin.内皮素
Pharmacol Rev. 2016 Apr;68(2):357-418. doi: 10.1124/pr.115.011833.
9
Possible role for nephron-derived angiotensinogen in angiotensin-II dependent hypertension.肾单位源性血管紧张素原在血管紧张素 II 依赖性高血压中的可能作用。
Physiol Rep. 2016 Jan;4(1). doi: 10.14814/phy2.12675.
10
Endothelin-1 as a master regulator of whole-body Na+ homeostasis.内皮素-1作为全身钠稳态的主要调节因子。
FASEB J. 2015 Dec;29(12):4937-44. doi: 10.1096/fj.15-276584. Epub 2015 Aug 12.
J Am Soc Nephrol. 2011 Apr;22(4):763-72. doi: 10.1681/ASN.2010080869. Epub 2011 Mar 3.
4
Regulation of blood pressure and salt homeostasis by endothelin.内皮素对血压和盐稳态的调节。
Physiol Rev. 2011 Jan;91(1):1-77. doi: 10.1152/physrev.00060.2009.
5
Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial.使用诊室血压和动态血压得出的结果不一致:达鲁生坦抵抗性高血压试验报告。
Hypertension. 2010 Nov;56(5):824-30. doi: 10.1161/HYPERTENSIONAHA.110.156976. Epub 2010 Oct 4.
6
Bioimpedance spectroscopy for the estimation of body fluid volumes in mice.生物阻抗谱法估计小鼠体液容量。
Am J Physiol Renal Physiol. 2010 Jul;299(1):F280-3. doi: 10.1152/ajprenal.00113.2010. Epub 2010 May 12.
7
Avosentan for overt diabetic nephropathy.阿伏生坦治疗显性糖尿病肾病。
J Am Soc Nephrol. 2010 Mar;21(3):527-35. doi: 10.1681/ASN.2009060593. Epub 2010 Feb 18.
8
Contribution of endothelin A receptors in endothelin 1-dependent natriuresis in female rats.内皮素A受体在雌性大鼠内皮素1依赖性利钠作用中的贡献。
Hypertension. 2009 Feb;53(2):324-30. doi: 10.1161/HYPERTENSIONAHA.108.123687. Epub 2008 Dec 22.
9
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.阿曲生坦用于非转移性、激素难治性前列腺癌患者的3期随机对照试验。
Cancer. 2008 Nov 1;113(9):2478-87. doi: 10.1002/cncr.23864.
10
Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention.集合管内皮素A和B受体联合敲除导致高血压和钠潴留。
Am J Physiol Renal Physiol. 2008 Dec;295(6):F1635-40. doi: 10.1152/ajprenal.90279.2008. Epub 2008 Sep 10.